Sheth, Safety of Intranasal Steroids in Treatment of Allergic Rhinitis 129 3. Dykewicz MS, Fireman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478–518. 4. Mahr TA, Sheth KK. Update on allergic rhinitis. Pediatr Rev 2005; 26:284–9. 5. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclo- methasone dipropionate. Pediatrics 2000;105(2):E23. 6. Murphy K, Rabinovitch N, Uryniak T, et al. Effect of once-daily budesonide aqueous nasal spray (BUD) on growth velocity in children [abstract]. J Allergy Clin Immunol 2004;113 Suppl:S175. 7. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105(2):E22. 8. Allen DB, Meltzer EO, Lemanske RF, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002;23:407–13. 9. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:56–62. 10. Gradman J, Caldwell MF, Wolthers OD. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short- term growth in children with allergic rhinitis. Clin Ther 2007;29: 1738–47. 11. Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 2005;115:940–5. 12. Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000;106(4 Suppl):S179–90. 13. Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic- pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics 2003;112(1 Pt 1):96–100. 14. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics 1993;92:594–9. 15. Wilson AM, Sims EJ, McFarlane LC, Lipworth BJ. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998; 102(4 Pt 1):598–604. 16. Ciclesonide [package insert]. Draft 19 Oct 2006. Available at: http://www.fda.gov/cder/foi/label/2006/022004lbl.pdf (accessed December 8 2007). 17. Allen A, Down G, Newland A, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 2007; 29:1415–20. 18. Tripathy I, Sterling R, Clements D, et al. Lack of effect on hypothalamic-pituitary-adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 mcg in children with perennial allergic rhinitis (PAR). J Allergy Clin Immunol 2007; 119(1):S232. 19. Patel D, Ratner P, Clements D, et al. Lack of effect on hypothalamic-pituitary-adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 mcg in adolescents and adults with perennial allergic rhinitis (PAR). J Allergy Clin Immunol 2007;119(1):S305. 20. Fluticasone furoate prescribing information. Available at: http:// us.gsk.com/products/assets/us_veramyst.pdf (accessed December 8 2007). 21. Derby L, Maier W. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 2000;105:912–6. 22. Sheth KK, Cook CK, Philpot EE, et al. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc 2004;25:115–20.